![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseAveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
-
Media ReleaseNovartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
-
Media ReleaseNovartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”
-
Media ReleaseNovartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
-
Media ReleaseNovartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
-
Media ReleaseNovartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma
-
Media ReleaseNovartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis
-
Media ReleaseNovartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
-
Media ReleaseNovartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
-
Media ReleaseNovartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosis
-
Media ReleaseNovartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
Pagination
- ‹ Previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- …
- 16
- › Next page